Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Fasting
- Prostatic Neoplasms
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 25 years and 89 years
- Gender
- Only males
Description
Prostate cancer is in Germany with approximately 25% of all cancers the most common cancer among man. Assumably there will be an increase in prostate cancer in the next few years because of demographic factors. The progressive metastatic prostate cancer often develops an androgen resistance. This so...
Prostate cancer is in Germany with approximately 25% of all cancers the most common cancer among man. Assumably there will be an increase in prostate cancer in the next few years because of demographic factors. The progressive metastatic prostate cancer often develops an androgen resistance. This so-called Castration-Resistant Prostate Cancer (CRPC) is not responsive to androgen deprivation therapy. Depending on symptoms and progression first-line chemotherapy - docetaxel and abiraterone are available. Intermittent fasting as a form of caloric restriction has been studied most extensively experimentally in recent years. It showed consistent beneficial effects on relevant inflammatory and oncological pathways. In the field of preclinical oncology research groups have recently focused on intermittent fasting with chemotherapeutic treatment and promising experimental data have been published. In summary, the combination of fasting and chemotherapy was more effective in various cancer animal models than chemotherapy alone.
Tracking Information
- NCT #
- NCT02710721
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Andreas Michalsen, Prof. Dr. Charite Centrum Epidemiologie und Gesundheitsökonomie, CC1: Gesundheitswissenschaften Principal Investigator: Kurt Miller, Prof. Dr. Charité Centrum Chirurgische Medizin, CC 8 Klinik für Urologie Principal Investigator: Ursula Steiner, Dr. Charité Centrum Chirurgische Medizin, CC 8 Klinik für Urologie